US NYSE

Archer-Daniels-Midland Company

Global agribusiness giant that restated six years of segment financials following an SEC probe into improper intersegment transfers boosting Nutrition profits.

CORPORATE IDENTIFIERS & DOSSIER
  • Entity Name: Archer-Daniels-Midland Company
  • Country of Domicile: US
  • Listing & Ticker: NYSE (ADM).
  • CIK / LEI Identifier: 0000007084.
  • Industry Classification: Fats, Oils, and Agribusiness (SIC 2070).
  • Cumulative Overstatement: $400.0M across 1 enforcement episode(s).
  • Assessed Penalties: $0.

PRIMARY ENFORCEMENT CASES INVOLVING ARCHER-DANIELS-MIDLAND COMPANY

1 CASE DOSSIERS
Case Title Status Primary Scheme Overstatement Total Penalties Action Date
Archer Daniels Midland: Intersegment Transfer Pricing & Nutrition Margin Shift Ongoing Proceedings segment misreporting $400.0M $0 September 20, 2025

FORENSIC PROFILE: ARCHER DANIELS MIDLAND: INTERSEGMENT TRANSFER PRICING & NUTRITION MARGIN SHIFT

FULL CASE DOSSIER →

Restated six years of intersegment sales after internal audit and SEC probes uncovered improper transfer pricing shifting operating profits into the high-growth Nutrition segment.

The company manipulated its accounting records by executing schemes under segment-misreporting. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.

Fraud Window: January 1, 2024 to December 31, 2025 • Primary Regulator: U.S. Securities and Exchange Commission • Auditor: Ernst & Young LLP

Documented Accounting Irregularities & Regulatory Findings

  • SEGMENT MISREPORTING: Restated six years of intersegment sales after internal audit and SEC probes uncovered improper transfer pricing shifting operating profits into the high-growth Nutrition segment.

Primary Public Dockets & Actions

  • [ENF-2024-adm] Enforcement Action: Archer Daniels Midland: Intersegment Transfer Pricing & Nutrition Margin Shift (September 20, 2025): Restated six years of intersegment sales after internal audit and SEC probes uncovered improper transfer pricing shifting operating profits into the high-growth Nutrition segment. Official Record ↗